Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Fallopian Tubes”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03029611
What this trial is testing

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

Who this might be right for
Stage III Fallopian Tube CancerStage III Ovarian CancerStage III Primary Peritoneal Cancer+12 more
University of Washington 11
Testing effectiveness (Phase 2)Study completedNCT04753216
What this trial is testing

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
Northwestern University 3
Not applicableStudy completedNCT00816387
What this trial is testing

Fallopian Tube Sperm Perfusion (FSP) Versus Intra-uterine Insemination (IUI) in Natural Cycle

Who this might be right for
Insemination, Artificial
IRCCS Burlo Garofolo 400
Testing effectiveness (Phase 2)Study completedNCT01199263
What this trial is testing

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
National Cancer Institute (NCI) 108
Testing effectiveness (Phase 2)Study completedNCT03759600
What this trial is testing

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Takeda 20
Large-scale testing (Phase 3)Looking for participantsNCT05281471
What this trial is testing

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Who this might be right for
Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerFallopian Tube Cancer+4 more
Genelux Corporation 186
Large-scale testing (Phase 3)Study completedNCT04908787
What this trial is testing

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 421
Testing effectiveness (Phase 2)UnknownNCT04846842
What this trial is testing

Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Lee's Pharmaceutical Limited 46
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Testing effectiveness (Phase 2)Ended earlyNCT01083537
What this trial is testing

Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer+1 more
University Health Network, Toronto 1
Not applicableStudy completedNCT04257045
What this trial is testing

Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

Who this might be right for
Breast CarcinomaDeleterious CDH1 Gene MutationDeleterious DICER1 Gene Mutation+6 more
M.D. Anderson Cancer Center 46
Testing effectiveness (Phase 2)Ended earlyNCT01685255
What this trial is testing

The IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Who this might be right for
Ovarian CancerGenitourinary (GU) Tumors
Incyte Corporation 83
Testing effectiveness (Phase 2)Study completedNCT00019552
What this trial is testing

Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT07460180
What this trial is testing

The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer

Who this might be right for
Ovarian CancerEpithelial CancerFallopian Tube Cancer
The Netherlands Cancer Institute 55
Early research (Phase 1)Ended earlyNCT00003382
What this trial is testing

Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT00010179
What this trial is testing

Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
NCIC Clinical Trials Group 81
Early research (Phase 1)Ended earlyNCT02485990
What this trial is testing

Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

Who this might be right for
Primary Peritoneal Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 24
Early research (Phase 1)Looking for participantsNCT07489287
What this trial is testing

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Roswell Park Cancer Institute 18
Not applicableUnknownNCT00958698
What this trial is testing

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaPsychological Impact of Cancer+1 more
Gynecologic Oncology Group 485
Testing effectiveness (Phase 2)Active Not RecruitingNCT05554328
What this trial is testing

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 165
Next Page